Rapid Micro Biosystems Expands Series C Round With Investment From EDBI

LOWELL, Mass., Aug. 11, 2015 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, a leading provider of automated, non-destructive, rapid microbial detection, today announced the expansion of its recent Series C equity financing with an investment from EDBI, the dedicated corporate investment arm of the Singapore Economic Development Board. This investment will be used to expand global commercial and manufacturing operations in support of the Rapid Micro Biosystems Growth DirectTM, an industry-leading system for faster detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, medical device and personal care products.

The Growth Direct™ System detects microbial contamination earlier across all key applications of environmental monitoring, bioburden and sterility testing, delivering compelling economic benefits to healthcare product manufacturers while improving their microbial quality processes. In use by some of the largest organizations in the world, the Growth Direct™ System is the first and only automated technology that addresses all microbial quality control applications and fits with current regulatory practices.

"With our growing customer base in Asia, and specifically in Singapore, the partnership with EDBI will accelerate Rapid Micro Biosystems’ strategic focus of growing our commercial and operational capabilities in the region,” said Robert Spignesi, CEO of Rapid Micro Biosystems.

“Rapid Micro Biosystems will enable Singapore’s pharmaceutical and medical technology plants to capture substantial and sustainable productivity gains. We are excited to assist the company in gaining access to the fast-growing Asian market from Singapore through our network in the region,” said Chu Swee Yeok, CEO and President of EDBI.

About Rapid Micro Biosystems
Rapid Micro Biosystems delivers the Growth Direct™ System, an automated, non-destructive rapid detection and enumeration technology based on the compendial method for microbial quality control in pharmaceutical manufacturing. The system automates and accelerates detection and enumeration in the areas of sterility testing, environmental monitoring, and bioburden testing, eliminating manual steps and analysis. The detection technology, first developed and patented by Dr. Don Straus, Ph.D., uses the natural auto-fluorescence of microbes and requires no reagents. For more information about Rapid Micro Biosystems visit www.rapidmicrobio.com

Contact: Mark Severns Rapid Micro Biosystems 978-349-3200 mseverns@rapidmicrobio.com

Primary Logo

Help employers find you! Check out all the jobs and post your resume.

Back to news